Manufacturer record

Zydus Healthcare Ltd: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

4 batches manufactured by Zydus Healthcare Ltd (Himachal Pradesh) were declared Not of Standard Quality between January 2020 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

4 records linked to Zydus Healthcare Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
4Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Jan 2020 to Jul 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

4
NSQ batches since 2020
2
Products affected
Dissolution
Most common failure
Jul 2026
Latest alert

Flagged batches per year

2020 · 12025 · 22026 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Diclofenac Sodium and Paracetamol Tablets IP I501103Mfg 2025-02 · Exp 2027-01 Description & DissolutionDissolution Lucknow LabState lab Jul 2026
Diclofenac Sodium and Paracetamol Tablets IP I405175Mfg 2024-10 · Exp 2026-09 Assay & DissolutionAssay Government of NCT of DelhiState lab Sep 2025
Diclofenac Sodium and Paracetamol Tablets IP I405175Mfg 2024-10 · Exp 2026-09 Assay & DissolutionAssay Government of NCT of DelhiState lab Sep 2025
Depotex 16 mg (Methylprednisolone Tablets IP) AFV1010Mfg 2019-03 · Exp 2021-02 DissolutionDissolution CDTL MumbaiCDSCO lab Jan 2020

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.